Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

9/3/24 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $QNCX alert in real time by email

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26^th Annual Global Investment Conference on September 9, 2024 beginning at 7 a.m. Eastern Time.

A webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com.

About Quince Therapeutics

Quince Therapeutics (NASDAQ:QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, X, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903061244/en/

Get the next $QNCX alert in real time by email

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Chat with this insight

Recent Analyst Ratings for
$QNCX

$QNCX
Market Insights

Live Market Insights

Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA

Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026

FDA Grants Fast Track Designation To Quince Therapeutics' EryDex System To Treat Ataxia-Telangiectasia

$QNCX
SEC Filings

$QNCX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$QNCX
Press Releases

Fastest customizable press release news feed in the world

SEC Form 8-K filed by Quince Therapeutics Inc.

SEC Form 10-Q filed by Quince Therapeutics Inc.

Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

SEC Form SC 13D filed by Quince Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

$QNCX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

$QNCX
Financials

Live finance-specific insights

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

$QNCX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

$QNCX
Leadership Updates

Live Leadership Updates

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Chat with this insight

Recent Analyst Ratings for $QNCX

$QNCX Market Insights

Live Market Insights

Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA

Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026

FDA Grants Fast Track Designation To Quince Therapeutics' EryDex System To Treat Ataxia-Telangiectasia

$QNCX SEC Filings

$QNCX Large Ownership Changes

This live feed shows all institutional transactions in real time.

$QNCX Press Releases

Fastest customizable press release news feed in the world

SEC Form 8-K filed by Quince Therapeutics Inc.

SEC Form 10-Q filed by Quince Therapeutics Inc.

Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

SEC Form SC 13D filed by Quince Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

$QNCX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

$QNCX Financials

Live finance-specific insights

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

$QNCX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

$QNCX Leadership Updates

Live Leadership Updates

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Recent Analyst Ratings for
$QNCX

$QNCX
Market Insights

$QNCX
SEC Filings

$QNCX
Large Ownership Changes

$QNCX
Press Releases

$QNCX
Insider Trading

$QNCX
Financials

$QNCX
Insider Purchases

$QNCX
Leadership Updates